Company intelligence / Profile preview

Cancuravax

Greenville, South Carolina, United States

Ownership: Private
Development stage: Other

Overview

Cancuravax was a clinical-stage biotechnology company that specialized in the development of personalized autologous cancer vaccines. The company's core technology involved the use of tumor lysate-particle loaded (TLPL) systems to present a broad spectrum of patient-specific tumor antigens to the immune system. Its lead programs targeted high-risk melanoma and other solid tumors, utilizing both dendritic cell-based and particle-only delivery methods. Cancuravax's research and clinical trials laid the groundwork for the TLPL platform currently being advanced by Orbis Health Solutions.

Therapeutic areas: Oncology
Modalities: VaccineBiologicCell therapyDendritic cell therapy
Industry: Biotech

Drug pipeline

2 assets

vaccinia melanoma cell lysate vaccine

Unknown

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Cancuravax.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cancuravax.

Explore the full profile